Clinical trial
Daily-Dose Consensus Interferon and Ribavirin: Efficacy of Combined Therapy
NCT00086541 · Bausch Health Americas, Inc., Industry · Completed
Key facts
| NCT number | NCT00086541 |
|---|---|
| Title | Daily-Dose Consensus Interferon and Ribavirin: Efficacy of Combined Therapy |
| Official title | A Phase 3, Randomized, Open-Label Study of the Safety and Efficacy of Two Dose Levels of Interferon Alfacon-1 (Infergen, CIFN) Plus Ribavirin Administered Daily for 48 Weeks Versus No Treatment in Hepatitis C Infected Patients Who Are Nonresponders to Previous Pegylated Interferon Alfa Plus… |
| Lead sponsor | Bausch Health Americas, Inc., Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Chronic Hepatitis C |
| Intervention type | Drug |
| Interventions | Daily Infergen (Interferon Alfacon-1, CIFN) (9 or 15 µg) + Ribavirin (1000-1200 mg, based on body weight) PO Daily for up to 48 wks |
| Enrollment | 515 |
| Start date | Jun 1, 2004 |
| Completion | Jan 1, 2007 |
| First posted | Jul 7, 2004 |
| Last update posted | Nov 25, 2019 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: